Company / FCF Margin
BridgeBio Pharma, Inc. FCF Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-89.0%
FY2025
5-year range
-733.2% / -89.0%
FY2021-FY2025
Trend
+62.1%
vs FY2024
Sector context
#86 of 133
Health Care
What the data says
At -89.0%, BridgeBio Pharma, Inc.'s fcf margin ranks #86 of 133 in the Health Care sector. FCF Margin has fluctuated over the past 7 years, ranging from -4936.7% in FY2020 to -89.0% in FY2025.
Based on SEC 10-K filings.
-89.0% in FY2025 with a 5-year CAGR of +4847.7%.
Improved from -733.2% to -89.0% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +457.4pp
- 5-Year Change
- +4847.7pp
- 10-Year Change
- -
Sector benchmark
#86 of 133 in Health CareTop 65% of 133This company -89.0% Sector average -632.8%
▼
+85.9% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 62.1% year-over-year.
- Currently 543.8pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -89.0% | +62.1% |
| FY2024 | -235.1% | +67.9% |
| FY2023 | -733.2% | -34.2% |
| FY2022 | -546.5% | +13.5% |
| FY2021 | -631.7% | +87.2% |
| FY2020 | -4936.7% | -681.5% |
| FY2019 | -631.7% | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026